TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m. ET WOBURN, Mass., Oct. 28, 2026 (GLOBE
WOBURN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it
NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP reminds purchasers of Replimune Group, Inc. (NASDAQ:REPL) securities of a pending securities class action on behalf of shareholders who purchased
NEW YORK CITY, NY / ACCESS Newswire / October 2, 2026 / Levi & Korsinsky, LLP alerts investors in Replimune Group, Inc. (NASDAQ:REPL) that a securities class action has been filed on behalf of shareholders who
WOBURN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that
Important Information Regarding Section 20(a) Individual Liability Claims: CEO Sushil Patel and CFO Emily Hill are named as individual defendants in a securities class action alleging Replimune's RP1 disclosures
Investors allege Replimune Group, Inc. built its RP1 regulatory strategy around single-arm trial designs the FDA had already questioned, including response criteria the agency said were not consistent with RECIST
If you purchased or acquired Replimune securities between October 20, 2025 and April 10, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- SueWallSt alerts investors in Replimune Group, Inc. (NASDAQ:REPL) of a pending securities class action on behalf of purchasers between October 20, 2025 and April 10,
San Diego, California--(Newsfile Corp. - September 28, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise
NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies institutional investors in Replimune Group, Inc. (NASDAQ:REPL) that a class action lawsuit has been filed on behalf of shareholders who
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ:REPL). Such investors are
Investors allege Replimune Group, Inc. told the market its RP1 resubmission was a complete response to the FDA's prior deficiency letter, while the agency's evidentiary standards for an "adequate and
Disclosure Under Scrutiny: Replimune's SEC filings warned generally that RP1 might not win approval, yet allegedly omitted that the FDA had already told the Company its study design concerns were unresolved.NEW
